Methotrexate is an antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.
Methotrexate is approved by the Food and Drug Administration (FDA) to be used by itself to treat the following types of gestational trophoblastic tumors, Chorioadenoma destruens, Choriocarcinoma, Hydatidiform mole. Methotrexate is also approved to be used alone or with other drugs to treat acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to keep it from spreading there, and to treat the following, breast cancer, certain types of head and neck cancer, lung cancer, advanced non-Hodgkin lymphoma (NHL), advanced mycosis fungoides (a type of cutaneous T-cell lymphoma), osteosarcoma that has not spread to other parts of the body, following surgery to remove the primary tumor. Methotrexate is also approved to treat the following non-cancer conditions, rheumatoid arthritis, severe psoriasis.
Leucovorin prescriptions for children spiked after federal officials claimed the drug was an effective treatment for autism during a September 2025 press conference, according to a new Michigan Medicine-led study published in The New England Journal of Medicine.
Chikungunya fever, caused by Chikungunya virus (CHIKV), has re‑emerged as a major global health threat. The 2025 outbreak in Guangdong, China – the largest local epidemic ever recorded – marks a critical epidemiological turning point.
Osteosarcoma is the most common primary bone cancer in children, adolescents, and young adults. Although chemotherapy and surgery have improved survival for localized disease, outcomes remain poor when tumors spread to the lungs or return after treatment.
Mixed histiocytosis (Langerhans cell histiocytosis [LCH] / Erdheim-Chester disease [ECD]) developing after treatment for initial skull LCH is not well recognized.
Breast cancer (BCA) is one of the most common cancers worldwide, with high mortality and morbidity in women.
First published in 2010, the EULAR recommendations for the management of RA, the most frequent inflammatory rheumatic disease, have been relied upon by healthcare professionals and organisations worldwide to offer an up-to-date and robust analysis of the effectiveness and practical use of available DMARDs – from conventional agents such as methotrexate to biologics and Janus kinase (JAK) inhibitors.
Knowledge graphs are a powerful tool for bringing together information from biological databases and linking what is already known about genes, diseases, treatments, molecular pathways and symptoms in a structured network.
A new review was published in Volume 12 of Oncoscience on September 4, 2025, titled "Prognostic significance of trophoblastic differentiation and β-hCG secretion in somatic malignancies of uterine corpus: A systematic review with survival analysis."
Children with a rare, debilitating muscle disease could benefit from the findings of new research by experts at UCL and Great Ormond Street Hospital (GOSH).
Virgin coconut oil and lauric acid show promise in inhibiting cancer cell growth and mitigating chemotherapy toxicity, paving the way for future therapies.
Immune-inflammatory skin diseases (e.g., psoriasis, atopic dermatitis) involve dysregulation of CD4+ T-cell subsets (Th1/Th2/Th17/Treg) and cytokine networks (IL-17/IL-23/IL-4).
A set of genes that could be used to help doctors predict which children will respond well to treatment for juvenile idiopathic arthritis (JIA) have been identified by researchers at UCL and Great Ormond Street Hospital for Children (GOSH), who are part of the CLUSTER Consortium.
Is there a benefit to early bDMARD? In psoriatic arthritis (PsA) EULAR - The European Alliance of Associations for Rheumatology - recommends a treat-to-target approach, and suggests more intensive therapy for people with poor prognostic factors, depending on the disease presentation.
Prednisone is recommended as the first-line treatment for pulmonary sarcoidosis, but this steroid causes a number of unwanted side effects.
A deeper understanding of osteosarcoma, the most common primary malignant bone tumor affecting children and adolescents, is reshaping strategies for overcoming treatment resistance.
Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders characterized by the clonal proliferation of cytotoxic lymphocytes. Among them, T-cell LGLL (T-LGLL) and NK-cell LGLL (NK-LGLL) are the most prominent.
Tecan Group today announced an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS, a subsidiary of the global life sciences and diagnostics company, Revvity Inc.
A new review uncovers how common natural supplements can both protect and endanger health, depending on dose, duration, and delivery—and points to next-gen technologies as the key to unlocking their full therapeutic power.
Drug-induced liver injury (DILI) is a significant concern in clinical practice, arising from medications, herbs, and dietary supplements.
Researchers develop targeted polymersomes loaded with methotrexate for the treatment of gestational choriocarcinoma,
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.